These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1779175)

  • 1. Role of gangliosides in active immunotherapy with melanoma vaccine.
    Ravindranath MH; Morton DL
    Int Rev Immunol; 1991; 7(4):303-29. PubMed ID: 1779175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO
    Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the antibody response to immunization with purified O-acetyl GD3 gangliosides in patients with malignant melanoma.
    Ritter G; Ritter-Boosfeld E; Adluri R; Calves M; Ren S; Yu RK; Oettgen HF; Old LJ; Livingston PO
    Int J Cancer; 1995 Sep; 62(6):668-72. PubMed ID: 7558412
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An epitope common to gangliosides O-acetyl-GD3 and GD3 recognized by antibodies in melanoma patients after active specific immunotherapy.
    Ravindranath MH; Morton DL; Irie RF
    Cancer Res; 1989 Jul; 49(14):3891-7. PubMed ID: 2472199
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ganglioside antigens expressed by human cancer cells.
    Ritter G; Livingston PO
    Semin Cancer Biol; 1991 Dec; 2(6):401-9. PubMed ID: 1810468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
    Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
    Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ; Guthmann MD; Gabri MR; Carnero AJ; Alonso DF; Fainboim L; Gomez DE
    Oncol Rep; 2002; 9(2):267-76. PubMed ID: 11836591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Gangliosides and cancer].
    Dumontet C; Portoukalian J
    Bull Cancer; 1991; 78(9):789-99. PubMed ID: 1751830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity of melanoma-associated gangliosides in cancer patients.
    Tai T; Cahan LD; Tsuchida T; Saxton RE; Irie RF; Morton DL
    Int J Cancer; 1985 May; 35(5):607-12. PubMed ID: 3997282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vaccines containing purified GM2 ganglioside elicit GM2 antibodies in melanoma patients.
    Livingston PO; Natoli EJ; Calves MJ; Stockert E; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1987 May; 84(9):2911-5. PubMed ID: 3472242
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Humoral immune response in disease-free advanced melanoma patients after vaccination with melanoma-associated gangliosides. EORTC Cooperative Melanoma Group.
    Portoukalian J; Carrel S; Doré JF; Rümke P
    Int J Cancer; 1991 Dec; 49(6):893-9. PubMed ID: 1959994
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
    Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
    Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Construction of immunogenic GD3-conjugate vaccines.
    Helling F; Calves M; Shang Y; Oettgen HF; Livingston PO
    Ann N Y Acad Sci; 1993 Aug; 690():396-7. PubMed ID: 8368767
    [No Abstract]   [Full Text] [Related]  

  • 15. Tumor gangliosides as targets for active specific immunotherapy of melanoma in man.
    Morton DL; Ravindranath MH; Irie RF
    Prog Brain Res; 1994; 101():251-75. PubMed ID: 8029455
    [No Abstract]   [Full Text] [Related]  

  • 16. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
    Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
    Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunorecognition of different ganglioside epitopes on human normal and melanoma tissues.
    Bernhard H; Roth S; Bauerschmitz J; Meyer zum Büschenfelde KH; Dippold W
    Int J Cancer; 1992 Jun; 51(4):568-72. PubMed ID: 1376299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Very low density lipoproteins and interleukin 2 enhance the immunogenicity of 9-O-acetyl-GD3 ganglioside in BALB/c mice.
    Dumontet C; Rebbaa A; Portoukalian J
    J Immunol Methods; 1997 Aug; 206(1-2):115-23. PubMed ID: 9328574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal.
    Rosenthal R; Viehl CT; Guller U; Weber WP; Adamina M; Spagnoli GC; Heberer M; Zuber M
    J Am Coll Surg; 2008 Jul; 207(1):95-105. PubMed ID: 18589368
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunorecognition of ganglioside epitopes: correlation between affinity and cytotoxicity of ganglioside antibodies.
    Dippold W; Bernhard H
    Eur J Cancer; 1992; 28A(10):1605-10. PubMed ID: 1382491
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.